Bone Therapeutics

Foundation date

22/06/2006

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Bone Therapeutics is a leading cell therapy company addressing high unmet medical needs in the field of orthopaedics and bone diseases.

Bone Therapeutics has a broad, diversified portfolio of bone cell therapy solutions and viscosupplement in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation. Our technology is based on a unique, proprietary approach to bone regeneration which turns undifferentiated stem cells into “osteoblastic”, or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.

Our primary clinical focus is ALLOB ® , an allogeneic “off-the-shelf” cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. In addition, Bone Therapeutics is also developing an enhanced viscosupplement, JTA-004, for the treatment of knee osteoarthritis.

Bone Therapeutics is also conducting preclinical research on next generation products such as combined cell-matrix products for large bone defects and maxillofacial applications.

Upcoming events

Latest news

  • ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder

    19 hours ago

  • Confo Therapeutics awarded EUR 1.7M VLAIO grant to expand application of ConfoBody® drug discovery and development technology in rare diseases

    Tuesday June 28th 2022

  • MRM Health starts clinical trial with next-generation optimized consortium therapeutic MH002 in Pouchitis

    Tuesday June 28th 2022